Repligen Corp. (RGEN) gains 0.31% for July 21

Equities Staff  |

Repligen Corp. (NASDAQ: RGEN) shares gained 0.31%, or $0.63 per share, to close Wednesday at $203.60. After opening the day at $202.44, shares of Repligen. fluctuated between $203.88 and $197.48. 374,783 shares traded hands an increase from their 30 day average of 328,016. Wednesday's activity brought Repligen.’s market cap to $11,178,549,278.

Repligen. is headquartered in Waltham, Massachusetts..

About Repligen Corp.

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Visit Repligen Corp.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Repligen Corp. and to follow the company’s latest updates, you can visit the company’s profile page here: Repligen Corp.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content